Xenetic Biosciences (Xenetic Biosciences) Buyback Yield % : 0.00 (As of Jun. 13, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Xenetic Biosciences Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Xenetic Biosciences's current buyback yield was 0.00%.

Xenetic Biosciences Buyback Yield % Historical Data

The historical data trend for Xenetic Biosciences's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenetic Biosciences Buyback Yield % Chart

Xenetic Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Buyback Yield %

Get a 7-Day Free Trial

Xenetic Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Buyback Yield %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Xenetic Biosciences's Buyback Yield %

For the Biotechnology subindustry, Xenetic Biosciences's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xenetic Biosciences's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Xenetic Biosciences's Buyback Yield % falls into.

Xenetic Biosciences Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Xenetic Biosciences's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	0)	/
	=	N/A%

Xenetic Biosciences's annualized Buyback Yield for the quarter that ended in Mar. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0)	*	4	/
	=	N/A%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Mar. 2024) data.

Xenetic Biosciences Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Xenetic Biosciences's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Xenetic Biosciences (Xenetic Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenetic Biosciences Inc (NAS:XBIOW) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

XBIO:USA

Address

945 Concord Street, Framingham, MA, USA, 01701

Website

https://www.xeneticbio.com

Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.